BALAXI Q1 FY27 results at a glance
BALAXI PHARMA LTD Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹80.68 cr |
|---|
| Revenue YoY | +14.1% |
|---|
| Operating profit | ₹3.81 cr |
|---|
| Operating margin | 4.7% |
|---|
| Net profit | ₹1.3 cr |
|---|
| Net profit YoY | +347.2% |
|---|
| Net profit QoQ | +111.7% |
|---|
| Net margin | 1.6% |
|---|
| Basic EPS | ₹0.24 |
|---|
| TTM revenue | ₹280 cr |
|---|
| TTM net profit | ₹2.42 cr |
|---|
| TTM net margin | 0.9% |
|---|
BALAXI Q1 FY27 results: what the numbers say
BALAXI PHARMA LTD (BALAXI) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹80.68 cr and a net profit of ₹1.3 cr, translating into earnings per share of ₹0.24.
Compared with the same quarter a year earlier, revenue grew by +14.1% and net profit grew sharply by +347.2%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹3.81 cr, an operating margin of 4.7% versus 5.2% a year ago — a contraction of 0.5 percentage points.
BALAXI quarter-wise results table
Revenue
₹80.68 cr
+14.1% YoY
Net profit
₹1.3 cr
+347.2% YoY
Operating profit
₹3.81 cr
+3.5% YoY
BALAXI PHARMA LTD (BALAXI) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹80.68 cr | ₹3.81 cr | ₹1.3 cr | 4.7% | 1.6% | ₹0.24 | +347.2% | +111.7% |
| Q4 FY262026-03-31 | ₹70.71 cr | -₹0.52 cr | ₹0.61 cr | -0.7% | 0.9% | ₹0.11 | — | +100.9% |
| Q3 FY262025-12-31 | ₹72.54 cr | ₹2.53 cr | ₹0.31 cr | 3.5% | 0.4% | ₹0.06 | — | +45.9% |
| Q2 FY262025-09-30 | ₹56.18 cr | ₹0.68 cr | ₹0.21 cr | 1.2% | 0.4% | ₹0.04 | — | -28.0% |
| Q1 FY262025-06-30 | ₹70.74 cr | ₹3.69 cr | ₹0.29 cr | 5.2% | 0.4% | ₹0.05 | — | — |
| TTM (last 4 quarters) | ₹280 cr | ₹6.5 cr | ₹2.42 cr | 2.3% | 0.9% | ₹0.45 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
BALAXI quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
BALAXI PHARMA LTD quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹80.68 cr | ₹70.71 cr | ₹72.54 cr | ₹56.18 cr | ₹70.74 cr |
|---|
| Total expenses | ₹76.87 cr | ₹71.24 cr | ₹70.01 cr | ₹55.49 cr | ₹67.06 cr |
|---|
| Gross profit | ₹37.51 cr | ₹30.16 cr | ₹30.81 cr | ₹27.15 cr | ₹31.18 cr |
|---|
| Operating profit (EBIT) | ₹3.81 cr | -₹0.52 cr | ₹2.53 cr | ₹0.68 cr | ₹3.69 cr |
|---|
| Operating margin | 4.7% | -0.7% | 3.5% | 1.2% | 5.2% |
|---|
| Interest cost | ₹0.73 cr | ₹0.99 cr | ₹1.02 cr | ₹0.89 cr | ₹1.01 cr |
|---|
| Profit before tax | ₹2.09 cr | ₹1.4 cr | ₹1.61 cr | ₹1.38 cr | ₹0.9 cr |
|---|
| Tax expense | ₹0.79 cr | ₹0.79 cr | ₹1.3 cr | ₹1.17 cr | ₹0.61 cr |
|---|
| Effective tax rate | 37.9% | 56.3% | 81.1% | 84.8% | 67.9% |
|---|
| Net profit (PAT) | ₹1.3 cr | ₹0.61 cr | ₹0.31 cr | ₹0.21 cr | ₹0.29 cr |
|---|
| Net profit margin | 1.6% | 0.9% | 0.4% | 0.4% | 0.4% |
|---|
| Basic EPS | ₹0.24 | ₹0.11 | ₹0.06 | ₹0.04 | ₹0.05 |
|---|
| Diluted EPS | ₹0.24 | ₹0.11 | ₹0.06 | ₹0.04 | ₹0.05 |
|---|
BALAXI results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +14.1% | — | — | — | — |
|---|
| Revenue QoQ | +14.1% | -2.5% | +29.1% | -20.6% | — |
|---|
| Operating profit YoY | +3.5% | — | — | — | — |
|---|
| Operating profit QoQ | +826.8% | -120.7% | +269.8% | -81.4% | — |
|---|
| Net profit YoY | +347.2% | — | — | — | — |
|---|
| Net profit QoQ | +111.7% | +100.9% | +45.9% | -28.0% | — |
|---|
| EPS YoY | +380.0% | — | — | — | — |
|---|
| EPS QoQ | +118.2% | +83.3% | +50.0% | -20.0% | — |
|---|
BALAXI annual results history
Full-year performance for BALAXI PHARMA LTD, useful for reading each quarter in context.
BALAXI PHARMA LTD annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹270 cr | ₹293 cr | ₹241 cr | ₹336 cr |
|---|
| Total expenses | ₹263 cr | ₹256 cr | ₹196 cr | ₹281 cr |
|---|
| Gross profit | ₹118 cr | ₹127 cr | ₹113 cr | ₹134 cr |
|---|
| Operating profit (EBIT) | ₹7.48 cr | ₹36.4 cr | ₹45.79 cr | ₹55.66 cr |
|---|
| Operating margin | 2.8% | 12.4% | 19.0% | 16.5% |
|---|
| Interest cost | ₹3.9 cr | ₹2.93 cr | ₹1.68 cr | ₹0.5 cr |
|---|
| Profit before tax | ₹5.29 cr | ₹28.67 cr | ₹2.02 cr | ₹56.92 cr |
|---|
| Tax expense | ₹3.88 cr | ₹3.6 cr | ₹4.4 cr | ₹10.96 cr |
|---|
| Effective tax rate | 73.2% | 12.6% | 218.4% | 19.3% |
|---|
| Net profit (PAT) | ₹1.42 cr | ₹25.07 cr | -₹2.39 cr | ₹45.96 cr |
|---|
| Net profit margin | 0.5% | 8.6% | -1.0% | 13.7% |
|---|
| Basic EPS | ₹0.26 | ₹4.54 | ₹-2.32 | ₹9.16 |
|---|
| Diluted EPS | ₹0.26 | ₹4.54 | ₹-2.32 | ₹9.08 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹80.68 cr against ₹70.74 cr in Q1 FY26, and ₹70.71 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +14.1%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹76.87 cr, or 95.3% of revenue, with operating profit grew +3.5% year on year.
Margins, tax and profitability
Net profit of ₹1.3 cr works out to a net margin of 1.6% compared with 0.4% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, BALAXI PHARMA LTD reported profit before tax of ₹2.09 cr, a tax charge of ₹0.79 cr (effective rate 37.9%), interest cost of ₹0.73 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹0.61 cr in Q4 FY26 to ₹1.3 cr in Q1 FY27, a change of +111.7%.
Trailing twelve months and annual context
Across the trailing four quarters BALAXI PHARMA LTD has generated revenue of ₹280 cr and net profit of ₹2.42 cr, a trailing net margin of 0.9%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹270 cr with net profit of ₹1.42 cr and EPS of ₹0.26, versus the prior year where revenue declined -7.7% and profit declined -94.3%.
What to watch in the next BALAXI quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
BALAXI PHARMA LTD has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
BALAXI results coverage
No results report published for BALAXI yet — our desk covers each quarter within minutes of the filing.
BALAXI quarterly results FAQs
What were BALAXI PHARMA LTD (BALAXI) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), BALAXI PHARMA LTD reported revenue of ₹80.68 cr and net profit of ₹1.3 cr, a change of +347.2% year on year on +14.1% revenue growth. EPS stood at ₹0.24.
What is BALAXI profit margin in Q1 FY27?
BALAXI PHARMA LTD posted a net profit margin of 1.6% and an operating margin of 4.7% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹280 cr and net profit ₹2.42 cr.
Did BALAXI results beat the previous quarter?
BALAXI PHARMA LTD net profit changed +111.7% quarter on quarter, from ₹0.61 cr in Q4 FY26 to ₹1.3 cr in Q1 FY27.
When are BALAXI PHARMA LTD (BALAXI) quarterly results?
BALAXI PHARMA LTD has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see BALAXI latest quarterly results?
Results coverage for BALAXI will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the BALAXI stock page.
What is BALAXI PHARMA LTD annual revenue and profit?
For FY26, BALAXI PHARMA LTD reported full-year revenue of ₹270 cr and net profit of ₹1.42 cr, with EPS of ₹0.26.
How many quarterly results has BALAXI declared recently?
Past results dates for BALAXI will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 11 Sept 2026. For information only, not investment advice.
